FDA Meeting Feedback Puts Turn Biotechnologies on Track to be First Longevity Company Taking Cell Rejuvenation Therapy to Clinic

FDA INTERACT meeting reviews Turn Bio's ERA™ and eTurna™ technologies, approach and plans, paving way toward its INDCompany continues to pace industry's cell regeneration therapy progressView original content:https://www.prnewswire.co.uk/news-releases/fda-meeting-feedback-puts-turn-biotechnologies-on-track-to-be-first-longevity-company-taking-cell-rejuvenation-therapy-to-clinic-301965847.html

en | boerse | 67990487 |